PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
522.30%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
230.56%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
230.56%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
243.75%
Interest expense growth above 10% signals concerning debt expansion. Seth Klarman would demand justification.
418.75%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
-202.01%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-176.90%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-176.90%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
89.62%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
89.62%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
2567.99%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
2567.99%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.